Dipyridamole and Adenosine Interaction
Drug interaction information between Dipyridamole and Adenosine.
Dipyridamole and Adenosine have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Dipyridamole and Adenosine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Dipyridamole causes adenosine levels to build up in the blood, which can make the effects on your heart and blood vessels stronger.
What To Do
Your doctor may need to change your dose of adenosine if you are also taking dipyridamole.
FDA Label Information
Adenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A 2A -receptor agonist.
Dipyridamole Also Interacts With
- Heparin moderate
- Warfarin moderate
- Enoxaparin minor
- Nicardipine minor
Frequently Asked Questions
Can I take Dipyridamole and Adenosine together?
This is a minor interaction. Your doctor may need to change your dose of adenosine if you are also taking dipyridamole.
How serious is the interaction between Dipyridamole and Adenosine?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Dipyridamole and Adenosine interact?
Dipyridamole causes adenosine levels to build up in the blood, which can make the effects on your heart and blood vessels stronger.
Understanding the Dipyridamole and Adenosine Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Dipyridamole belongs to the Antiplatelet / Vasodilator class and Adenosine belongs to the Endogenous Nucleoside (Antiarrhythmic) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Dipyridamole causes adenosine levels to build up in the blood, which can make the effects on your heart and blood vessels stronger. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Dipyridamole has 5 total documented interactions on file in this dataset, and Adenosine has 2. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to change your dose of adenosine if you are also taking dipyridamole. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Dipyridamole or Adenosine based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.